NCT06675864进行中（未招募）1 期
An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 28
- 试验地点
- 37
- 主要终点
- Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs)
研究概览
简要总结
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
详细描述
All participants in this study will receive YTB323. Both the participant and the study doctor will know the participant is getting YTB323. Participants will be given one dose of YTB323. Different groups of participants may receive a higher dose of YTB323, if proven to be safe for every participant at the lower dose. Participants are in this study for 2 years and will be followed for an additional 13 years in a long-term follow up study. The main question this trial is designed to answer: Is YTB323 treatment safe for participants with progressive MS?
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants 18 to 60 years (inclusive) at screening.
- •Signed informed consent must be obtained prior to participation in the study.
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study including:
- •Able to undergo lumbar puncture (LP), blood draws, tolerate brain and spinal MRI, and able to participate and tolerate all study procedures at study visits.
- •Diagnosis of SPMS or PPMS according to the 2017 McDonald diagnostic criteria (Thompson et al 2018) as confirmed at screening visit.
- •Less than 15 years (inclusive) from onset of first MS symptoms as determined by the investigator during screening.
- •Ambulatory Patients (EDSS 3 to 6.5 inclusive) at screening.
- •Evidence of recent (within 24 months) disease progression of ≥1.00 on the EDSS scale.
- •No relapse in the last 24 months at screening.
- •No Gd-enhancing lesion on brain or spinal cord MRI at screening.
- •Participants must receive or be current on all recommended vaccinations according to institutional, local, or global guidelines for immunocompromised patients at least 6 weeks prior to lymphodepletion.
排除标准
- •Diagnosis of relapsing multiple sclerosis (RMS) or active PMS according to the 2017 revision of the McDonald diagnostic criteria (Thompson et al 2018) at screening.
- •History of, or current, clinically significant CNS disease except MS (e.g. stroke, traumatic brain or spinal injury, history or presence of myelopathy, history of seizures or epilepsy) or neurological disorders which may mimic MS at screening.
- •Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, New York Heart Association Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 6 months prior to or during screening).
- •Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or neurological symptoms consistent with PML prior to or during screening.
- •Clinically significant, active, opportunistic, chronic or recurrent infection (including positive for hepatitis B or hepatitis C) confirmed by clinical evidence, imaging, or positive laboratory tests one month prior to leukapheresis.
- •Have donated blood or experienced a loss of blood > 400 mL within 3 months prior screening, or longer if required by local regulations.
- •Any prior stem cell therapy or organ transplantation or gene therapy.
- •Any contraindications to LP, including but not limited to:
- •Known or suspected structural abnormality of the lumbar spine that, in the opinion of the Investigator, may interfere with the performance of the LP, or increase the risk of the procedure for the participant.
- •Presence of risk for increased or uncontrolled bleeding (including but not limited to vascular abnormalities or neoplasms at or near the LP site, disorders of the coagulation cascade, platelet function, or platelet count).
- •Participants on anticoagulants (e.g., warfarin) or antiplatelets [except for low-dose aspirin (100 mg/day or lower) and low-dose nonsteroidal anti-inflammatory drugs such as ibuprofen (600 mg/day or lower) which are allowed], are not eligible to participate.
- •Not willing or able to have MRI scans as per protocol e.g. due to claustrophobia, or absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).
- •Pregnant or nursing (lactating) women.
- •Past surgical history of splenectomy.
- •Evidence of active or latent tuberculosis (TB) infection by QuantiFERON® TB-Gold assay (or equivalent) performed at Screening by central lab. In case of unclear or indeterminate test results, the Investigator should consult with an infectious disease expert to exclude the diagnosis of active or latent TB infection and document this in the source data. Participant should be excluded if they have any signs of active TB observed in available lung imaging (e.g., X-ray or HRCT).
- •Any psychiatric, pulmonary (including, history of or active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis), renal, hepatic, endocrine, metabolic (e.g. severe hypoproteinemia due to nephrotic syndrome), hematological disorders or gastrointestinal disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant, prior to or during screening.
- •Grade 2 or higher thromboembolic event in the past 4 weeks prior to or during Screening or evidence of disorders of coagulation or platelet function including subjects that require chronic use of anticoagulation or antiplatelet drugs (please refer to the key exclusion criteria no. 8 for the exceptions).
研究组 & 干预措施
YTB323 Cohort 3
Experimental
Participants will receive one dose of YTB323
干预措施: rapcabtagene autoleucel (YTB323) (Biological)
YTB323 Cohort 4
Experimental
Participants will receive one dose of YTB323
干预措施: rapcabtagene autoleucel (YTB323) (Biological)
YTB323 Cohort 1
Experimental
Participants will receive one dose of YTB323
干预措施: rapcabtagene autoleucel (YTB323) (Biological)
YTB323 Cohort 2
Experimental
Participants will receive one dose of YTB323
干预措施: rapcabtagene autoleucel (YTB323) (Biological)
结局指标
主要结局
Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs)
时间窗: Day 1 through Year 2
Occurrence, severity, and frequency of dose limiting toxicities (DLTs), AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs), laboratory parameters, neurological status and magnetic resonance (MRI) of the brain and spinal cord qualifying and reported as AEs.
次要结局
- Measure of Disability: Expanded Disability Status Scale (EDSS).(Day 1 through Year 2)
- Measure of Disability: Short Form Health Survey (SF-36 v2)(Day 1 through Year 2)
- Measure of Disability: Timed 25 Foot Walk (T25FW)(Day 1 through Year 2)
- Measure of Disability: 9 Hole Peg Test (9HPT)(Day 1 through Year 2)
- Measure of Disability: Symbol Digit Modalities Test (SDMT)(Day 1 through Year 2)
- Modified Fatigue Impact Scale (MFIS)(Day 1 through Year 2)
- Whole Blood Pharmacokinetics (PK) of YTB323 - CMAX(Day 1 through Year 2)
- Whole Blood Pharmacokinetics (PK) of YTB323 - AUC(Day 1 Through Year 2)
- Whole Blood Pharmacokinetics (PK) of YTB323 - Tmax(Day 1 Through Year 2)
- Whole Blood Pharmacokinetics (PK) of YTB323 - Clast(Day 1 Through Year 2)
- Whole Blood Pharmacokinetics (PK) of YTB323 - Tlast(Day 1 through Year 2)
- Humoral Immunogenicity of YTB323(Day 1 through Year 2)
- Cellular Immunogenicity of YTB323(Day 1 through Year 2)
- Safety data including dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) from each dose level(Day 1 through Year 2)
- Change from baseline for clinical measures of disability (includes EDSS, T25FW, 9HPT, SDMT).
- YTB323 transgene expression levels by qPCR over time in blood; cellular kinetics parameters (Cmax, AUC, Tmax, Clast, Tlast).
- Safety data from each dose level.
- Pre-existing and treatment-induced immunogenicity (humoral, anti-YTB323 antibody; and cellular, presence of CAR19 specific CD4 and CD8 T cells measuring interferon gamma production).
研究者
研究点 (37)
Loading locations...
相似试验
已完成
1 期
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentNon-Small-Cell Lung CarcinomaNCT01801111Hoffmann-La Roche138
招募中
1 期
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)Duchenne Muscular DystrophyNCT06138639Solid Biosciences Inc.60
终止
1 期
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)Advanced Hepatocellular CarcinomaNCT01942083Korea Otsuka Pharmaceutical Co., Ltd.33
招募中
1 期
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineBladder CancerNCT04799847LintonPharm Co.,Ltd.161
进行中（未招募）
1 期
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesPart 1：r/r B-cell MalignanciesPart 2：B-cell MalignanciesNCT04014205Beijing InnoCare Pharma Tech Co., Ltd.81